Linker Information
General Information of This Linker
| Linker ID |
LIN0LJYEO
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
H-disulfide linker
|
|||||
| Linker Type |
Thiol-sensitive linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
HER2-LC-H-SS-PBD [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 63.00% (Day 24) | High HER2 expression (HER2+++) | ||
| Method Description |
All animals were euthanized before tumors reached 3000 mm3 or showed signs of impending ulceration. Mice were dosed IV via the tail vein with ADC conjugates A1-A4. A1 and A2 were dosed at 4 mg/kg.
|
||||
| In Vivo Model | MMTV-HER2 Fo5 CDX model (Trastuzumab resistant) | ||||
| In Vitro Model | Breast cancer | MMTV-HER2 cells | Mus musculus | ||
HER2-HC-H-SS-PBD [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.00% (Day 24) | High HER2 expression (HER2+++) | ||
| Method Description |
All animals were euthanized before tumors reached 3000 mm3 or showed signs of impending ulceration. Mice were dosed IV via the tail vein with ADC conjugates A1-A4. A1 and A2 were dosed at 4 mg/kg.
|
||||
| In Vivo Model | MMTV-HER2 Fo5 CDX model (Trastuzumab resistant) | ||||
| In Vitro Model | Breast cancer | MMTV-HER2 cells | Mus musculus | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.